Skip to Content

Skin/Melanoma Trials

E3612: A Randomized Phase II Trial of Ipilimumab with or without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma
Aims: The purpose of this research study is to compare the good and bad effects of using the study drug called ipilimumab either alone or in combination with the study drug called bevacizumab. This regimen could help improve how long you are able to live with your cancer, but it could also cause side effects. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach used to treat advanced melanoma. Ipilimumab is approved by the FDA at a dose of 3 mg/kg for a total of 4 doses given 3 weeks apart for metastatic melanoma that cannot all be removed or treated with surgery. Bevacizumab is not approved by the FDA to treat melanoma, and is an investigational treatment. There will be about 168 people taking part in this study. Ten of those patients will be from NorthShore University HealthSystem.
Diagnosis: Unresectable Stage III or Stage IV Melanoma
Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH14-171
Sponsor: Eastern Cooperative Oncology Group
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib follwed by Ipilumumab + Nivolumab at Progression vs. Ipilumumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma
Aims: This study will test which treatment to receive first and the potential sequence of treatments for melanoma
Diagnosis: Melanoma
Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH17-194
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Elita Fine at 847.570.2698
Open to Enrollment: Yes

EA6141: A Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma  
Aims: The purpose of this research study is to compare any good and bad effects of giving ipilimumab, nivolumab and GM-CSF (Sargramostim) at the same time compared to just ipilimumab and nivolumab. 
Diagnosis:  Melanoma
Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH16-200
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

S1404: A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma
Aims: The purpose of this research study is to compare the good and bad effects of using the study drug called pembrolizumab  to the usual treatment of interferon alfa-2b.
Diagnosis:  Melanoma
Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH16-154
Sponsor: Southwest Oncology Group
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

UC15-1788: A Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody
Aims: The purpose of this research study is determine whether pembrolizumab in combination with ipilumumab is an effective regimen for subjects who have previously received an anti-PD1 antibody such as pembrolizumab or nivolumab.
Diagnosis:  Melanoma
Principal Investigator: Bruce Brockstein, MD 
IRB Approval Number: EH17-086
Sponsor: University of Chicago
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

S1320: A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma
Aims: The purpose of this research study is to compare the good and bad effects of having a break in treatment with dabrafenib and trametinib comparing to continous treatment.
Diagnosis:  Melanoma
Principal Investigator: Bruce Brockstein, MD 
IRB Approval Number: EH17-074
Sponsor: Southwest Oncology Group 
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

BMS CA209-357: A US Prospective Multi-Site Observational Study in Patients with Unresectable and Metastatic Melanoma: The OPTIMIZE study.
Aims: The purpose of this research study is to collect information on the the treatment and management of advanced melanoma.
Diagnosis: Melanoma
Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH16-042
Sponsor: Bristol-Myers- 
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes